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1. Introduction
Liver biopsy remains a golden standard in the evaluation of various liver diseases. It is one
of the most specific test allowing to assess the severity of various liver diseases. Clinical
evaluation may be inadequate as chronic liver diseases could be asymptomatic for a long pe‐
riod of time. The routinely used laboratory test may be irrelevant, as diffuse changes may
possibly be present in the liver in spite of liver function test being within reference values.
Percutaneous biopsy allows to obtain a tissue specimen suitable for pathological assessment.
Liver biopsy is an important procedure in diagnosing liver diseases in infants and children
as it often provides diagnostic information not possible to obtain by other methods. There‐
fore, liver biopsy is considered to be a golden standard in the diagnostics and follow-up of
the patients with chronic diffuse hepatopathies. The role of the liver biopsy is to confirm the
diagnosis of chronic hepatitis, assess the necroinflamatory activity (grading) and the severi‐
ty of fibrosis (staging), confirm the presence of cirrhosis. Other hepatopathies may be ex‐
cluded as well as associated diseases using this method [1].
The size of liver sample varies from 1 to 4 cm in length and 1.2 to 1.8 mm in diameter. Biop‐
sy specimen represents 1/50,000 of the total mass of the liver, therefore the procedure carries
the risk of sampling error. The specimen should be sufficient in length (2-2.5 cm) and num‐
ber of portal spaces (at least 11). The fragmentation of the specimen should be avoided [2].
Liver assessment is also affected by an interpretative error and intraobserver variability of
histological interpretation. Moreover, liver biopsy is an invasive procedure carrying the risk
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of certain complications including pain, bleeding, pneumothorax, puncture of bile ducts or
the gall bladder.
Repeating samples in different time intervals are useful in monitoring the efficacy of treat‐
ments. Many patients are, however, reluctant to experience repeated biopsies, which limits
the ability to monitor disease progression and treatment effects. [3].
Due to the limitations of the procedure many non-invasive techniques were developed such
as single serological markers, panels of different markers, imaging techniques and elastogra‐
phy [4]. None of the non-invasive methods is suitable and reliable enough to entirely substi‐
tute the liver biopsy. Non-invasive techniques are very helpful in the detection of severe
lesions. However, results obtained from patients with intermediate lesions very often over‐
lap between different categories of staging. Nevertheless non-invasive methods are useful in
situations where contraindications to liver biopsy do not allow to perform the procedure.
Liver biopsy can be percutaneous, transjugular or laparoscopic. Percutaneous liver biopsy
can be blind, ultrasound- guided or ultrasound assisted. Various approaches differ in the
number of potential complications and require various equipment. Ultrasound guidance al‐
lows safer intercostal approach and may be useful in the evaluation of relative position of
the liver, gall bladder, kidneys and lungs. The technique reduces the risk of hemothorax and
pneumothorax and puncture of the gall bladder.
The aim of this study was to evaluate safety and reliability of the liver biopsy in children in
relation to obtained results and potential complications.
2. Material and methods
Seventy five cases of percutaneous liver biopsies carried between 2005-2012 were analyzed.
The biopsies were performed in children aged 4-17 years (mean 15.30±2.35 years). Study
group included 26 girls, 49 boys. Procedures were done due to chronic hepatitis C (CHC) –
44 cases, chronic hepatitis B (CHB) – 16 cases, autoimmune hepatitis (AIH) – 3 cases, hepati‐
tis/hepatomegaly of unknown origin (HUO)– 12 cases, non-alcoholic fatty liver disease
(NAFLD) – 2 cases. Number of the procedures performed in the following years has been
presented in Figure 1.
Written informed consent was obtained from the parents and patients aged 16 years and
over according to Polish law regulations. Before the procedure children were clinically eval‐
uated and blood samples were taken for standard hematological and clinical chemistry anal‐
ysis. Children with coagulopathies and thrombocytopenia below 80,000/mm3 were excluded
from the procedure. All children underwent abdominal ultrasound performed the day be‐
fore the procedure to exclude potential hemangiomas and malposition of the organs. All
children were managed by Menghini procedure in sedation. Children aged less than 5 years
received general anesthesia. 36 biopsies were ultrasound guided directly prior to the proce‐
dure (performed by the operator), 39 biopsies were blind. The ultrasound prior to the biopsy
was performed to identify the intercostal space and to avoid accidental puncture of the gall
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bladder, the lung, right kidney and large vessels. Immediately after the procedure ultra‐
sound examination was performed searching for potential complications such as accidental
puncture or bleeding. In the case of blind biopsied ultrasound examination was performed
by radiologists in situations where complications were suspected basing on clinical symp‐
toms. All patients were monitored 24 hours after the procedure in the department for vital
signs, pain and other consequences.
Histological evaluation was performed using Ishak scoring system for grading and staging.
Categorical variables were compared using Fisher’s exact test or chi-square test were appro‐
priate. Result with p value <0.05 were considered statistically significant.
Figure 1. Number of liver biopsy performed in the Department of Infectious Diseases and Child Neurology due to vari‐
ous reasons in years 2005-2012 (until July) CHC- chronic hepatitis C, CHB – chronic hepatitis B, NAFLD – non-alcoholic
fatty liver disease, HUO – hepatitis/hepatomegaly of unknown origin, AIH – autoimmune hepatitis
3. Results
Liver samples were obtained in all children. Adequate sample size was not obtained in the
case of 5 children - 2 samples were to short and did not contain the adequate number of por‐
tal spaces, one sample was fragmented. Four inadequate samples resulted from the blind
liver biopsy and 1 was obtained by the ultrasound guided procedure (p=0.21). No significant
adverse events were observed. No clinical signs of hemorrhage, no cases of pneumothorax,
puncture of the gallbladder nor severe infections were observed. Larger bile ducts were
punctured in 4 cases – all undergoing blind procedure (p=0.07). 12 patient were complaining
on pain in the right upper quadrant of the abdomen following the procedure that required
more intensive analgesics – 3 undergoing ultrasound guided procedure, 9 having blind liver
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biopsy done (p=0.07). Pain was mild to moderate and resolved after analgesics. There were
no deaths following the procedure in both groups of children.
Results from pathological assessment were presented in Table 1. The majority of children
underwent liver biopsy due to CHC. Remaining indications were CHB, AIH, NAFLD, HUO.
In patients with viral hepatitis grading and staging assessed according to Ishak scoring sys‐
tem was usually mild to moderate. Nevertheless, severe lesions were also present in some
patients. Figure 2 and Figure 3.show examples of inflammatory changes and portal fibrosis
in various patients with CHC. In patients with AIH and NAFLD diagnosis was confirmed
by pathological assessment. Ten of HUO patients gained diagnosis either of metabolic disor‐
ders or NAFLD thanks to pathological evaluation. Normal liver histology was described in 2
patients.
Figure 2. Liver biopsy specimen of the patient with CHC where inflammatory infiltrates cross lamina basalis of the lo‐
buli (thin arrows) and intralobular focus of inflammatory infiltrate (thick arrow).Staining: hematoxylin+eosine. Magni‐
fication 40x
Fifteen children with viral hepatitis underwent repeated procedures allowing to assess the
progression of lesions in time. In 9 of them the progression of lesions was described, 6 had
similar results in both biopsies.
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Indication for the biopsy Result Number of children
CHC - 44
Grading
1 23
2 11
3 5
4 5
Staging
0 1
1 19
2 17
3 5
4 2
CHB - 16
Grading
1 3
2 8
3 3
4 2
Staging
1 3
2 7
3 5
4 1
NAFLD - 2 Steatosis 1Steatohepatitis 1
HUO - 12
Metabolic disorders 3
Nonalcoholic steatohepatitis 6
Wilson disease 1
Normal liver histology 2
AIH - 3 Autoimmune hepatitis 3
Table 1. Histological assessment of the liver biopsy specimens performed in 75 children. CHC- chronic hepatitis C, CHB
– chronic hepatitis B, NAFLD – non-alcoholic fatty liver disease, HUO – hepatitis/hepatomegaly of unknown origin, AIH
– autoimmune hepatitis
4. Discussion
Studies describing the safety of liver biopsy performed on larger cohorts of patients seem to
prove that the procedure results in more complications in children than in adults [5]. Never‐
theless, Lebensztejn et al. described the group of 250 pediatric patients undergoing blind
procedure with serious complications as internal hemorrhage and puncture of the gallblad‐
der occurring in 3 children [6].
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Figure 3. Syrius red staining of the liver specimen of CHC patient with present fibrosis in dilated portal space (thick
arrow) and porto-portal bridging. Magnification 40x.
Number of biopsies in the current study was lower, however even the number of mild com‐
plications was relatively low. Moreover, no serious adverse events were noted among chil‐
dren from the study group. Noted complications included puncture of larger bile ducts and
pain after the procedure. Although the results were not statistically significant, both prob‐
lems were more frequent in children undergoing blind liver biopsy. Ultrasound assistance
during the whole procedure was found to reduce the number of potential consequences [7].
Thus, ultrasound guidance even performed right before and after the biopsy makes the
whole procedure safer. Since the majority of complications occur within first hours after the
liver biopsy all children were monitored for 24 hours after the procedure as inpatients. Al‐
though hospitalization increases the costs of the procedure, monitoring enables quick re‐
sponse to encountered complications and prompt treatment, if necessary. Another issue is
general anesthesia performed in small children in order to obtain liver sample. Although
costly, general anesthesia decreases fear, pain and enables to perform the procedure in safe
circumstances, reducing the risk of hemorrhage caused by lack of cooperation from the pa‐
tient side.
Liver Biopsy – Indications, Procedures, Results80
The majority of children underwent the liver biopsy due to chronic viral hepatitis – mostly
CHC. Histological assessment was not necessary to establish diagnosis since it is usually
based on blood tests. However, information regarding grading and staging was essential for
treatment decisions since the length of treatment may vary depending on the severity of le‐
sions. In patients with CHB decisions regarding the initiation of the treatment may depend
on the presence of lesions in the liver tissue [8]. In both types of chronic viral hepatitis pa‐
tient with liver cirrhosis requires different approach than the child with mild lesions in the
liver. In children with AIH the diagnosis was confirmed by the detection of specific inflam‐
matory cells in the liver tissue. Although the number of NAFLD was small, the procedure
distinguished between simple steatosis and steatohepatitis. Patients who underwent the
procedure due to HUO benefited from diagnosis in 10/12 children. Metabolic disorders were
detected in 3 patients and steatosis was detected in 6 children, 1 child was found to have
Wilson’s disease. Normal liver histology found in the specimens from the following 2 chil‐
dren with HOU raises questions regarding indications to the liver biopsy. The decision con‐
cerning the procedure was always carefully made basing on clinical and laboratory findings.
Obtained results may be a consequence of the limitations of the procedure regarding sample
size and sample error related to the site of the biopsy. Diffuse liver diseases are hardly ever
evenly distributed in the organ.
Another problem with pathological assessment is an intraobserver variety. Except for skill‐
ful operator, an experienced pathologist is essential for proper evaluation of the samples.
However, differences in the assessment between to various pathologists are difficult to
avoid even with the use of validated scoring systems.
In recent years many non-invasive methods of liver assessment were developed. Imaging
techniques allow to describesteatosis, focal changes, malformations, inflammatory processes
of bile ducts and advanced fibrosis. Mild changes are, however, still difficult to detect. Elas‐
tography has been developed to evaluate liver stiffness being a useful tool to assess liver fib‐
rosis [9]. Fibrosis is also evaluated by different serological markers and panels of direct and
indirect markers or combination of both. Various cut-offs of the markers to detect advanced
fibrosis and cirrhosis were validated in numerous studies [4]. Nevertheless, problem with
intermediate stages of fibrosis still exist, since in such cases serological markers overlap.
Attempts to completely replace the biopsy with other non-invasive methods are not effec‐
tive as the collection of adequate liver sample and proper histological evaluation allows to
determine the extent ofthe liver damage and helps to establish the diagnosis.
5. Conclusions
Percutaneous liver biopsy is safe even in small children. Although severe complications are
rare, patients require frequent monitoring. Ultrasound guidance seem to reduce the number
of complications. Remaining a golden standard, the liver biopsy has certain limitations and
drawbacks that influence the results.
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